169 related articles for article (PubMed ID: 30219843)
1. Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.
Robertson KR; Jiang H; Kumwenda J; Supparatpinyo K; Marra CM; Berzins B; Hakim J; Sacktor N; Campbell TB; Schouten J; Mollan K; Tripathy S; Kumarasamy N; La Rosa A; Santos B; Silva MT; Kanyama C; Firhnhaber C; Murphy R; Hall C; Marcus C; Naini L; Masih R; Hosseinipour MC; Mngqibisa R; Badal-Faesen S; Yosief S; Vecchio A; Nair A;
Clin Infect Dis; 2019 May; 68(10):1733-1738. PubMed ID: 30219843
[TBL] [Abstract][Full Text] [Related]
2. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.
Robertson K; Jiang H; Kumwenda J; Supparatpinyo K; Evans S; Campbell TB; Price R; Tripathy S; Kumarasamy N; La Rosa A; Santos B; ; Silva MT; Montano S; Kanyama C; Faesen S; Murphy R; Hall C; Marra CM; Marcus C; Berzins B; Allen R; Housseinipour M; Amod F; Sanne I; Hakim J; Walawander A; Nair A;
Clin Infect Dis; 2012 Sep; 55(6):868-76. PubMed ID: 22661489
[TBL] [Abstract][Full Text] [Related]
3. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.
Robertson KR; Oladeji B; Jiang H; Kumwenda J; Supparatpinyo K; Campbell TB; Hakim J; Tripathy S; Hosseinipour MC; Marra CM; Kumarasamy N; Evans S; Vecchio A; La Rosa A; Santos B; Silva MT; Montano S; Kanyama C; Firnhaber C; Price R; Marcus C; Berzins B; Masih R; Lalloo U; Sanne I; Yosief S; Walawander A; Nair A; Sacktor N; Hall C;
Clin Infect Dis; 2019 May; 68(10):1739-1746. PubMed ID: 30137250
[TBL] [Abstract][Full Text] [Related]
4. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
[TBL] [Abstract][Full Text] [Related]
5. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ
AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
[TBL] [Abstract][Full Text] [Related]
7. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271.
Robertson K; Jiang H; Evans SR; Marra CM; Berzins B; Hakim J; Sacktor N; Silva MT; Campbell TB; Nair A; Schouten J; ; Kumwenda J; Supparatpinyo K; Tripathy S; Kumarasamy N; la Rosa A; Montano S; Mwafongo A; Firnhaber C; Sanne I; Naini L; Amod F; Walawander A;
J Neurovirol; 2016 Aug; 22(4):472-8. PubMed ID: 26733457
[TBL] [Abstract][Full Text] [Related]
8. Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.
Arenas-Pinto A; Stöhr W; Jäger HR; Haddow L; Clarke A; Johnson M; Chen F; Winston A; Godi C; Thust S; Trombin R; Cairns J; Solanky BS; Golay X; Paton NI;
Clin Infect Dis; 2016 Jul; 63(2):257-64. PubMed ID: 27143662
[TBL] [Abstract][Full Text] [Related]
9. Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.
Kalayjian RC; Robertson KR; Albert JM; Fichtenbaum CJ; Brown TT; Taiwo BO;
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):e49-e54. PubMed ID: 30939531
[TBL] [Abstract][Full Text] [Related]
10. Neurocognitive Impairment in Well-Controlled HIV-Infected Patients: A Cross-Sectional Study.
Portilla I; Reus S; León R; van-der Hofstadt C; Sánchez J; López N; Boix V; Merino E; Portilla J
AIDS Res Hum Retroviruses; 2019 Jul; 35(7):634-641. PubMed ID: 30880401
[TBL] [Abstract][Full Text] [Related]
11. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings.
Robertson K; Kumwenda J; Supparatpinyo K; Jiang JH; Evans S; Campbell TB; Price RW; Murphy R; Hall C; Marra CM; Marcus C; Berzins B; Masih R; Santos B; Silva MT; Kumarasamy N; Walawander A; Nair A; Tripathy S; Kanyama C; Hosseinipour M; Montano S; La Rosa A; Amod F; Sanne I; Firnhaber C; Hakim J; Brouwers P;
J Neurovirol; 2011 Oct; 17(5):438-47. PubMed ID: 21786076
[TBL] [Abstract][Full Text] [Related]
12. Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy.
Letendre S; Bharti A; Perez-Valero I; Hanson B; Franklin D; Woods SP; Gianella S; de Oliveira MF; Heaton RK; Grant I; Landay AL; Lurain N;
Clin Infect Dis; 2018 Aug; 67(5):770-777. PubMed ID: 29506084
[TBL] [Abstract][Full Text] [Related]
13. Psycho-behavioral factors associated with neurocognitive performance among people living with HIV on antiretroviral therapy in Accra, Ghana.
Asiedu N; Kretchy I; Asampong E
Afr Health Sci; 2020 Jun; 20(2):487-596. PubMed ID: 33163015
[TBL] [Abstract][Full Text] [Related]
14. Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda.
Vecchio A; Robertson K; Saylor D; Nakigozi G; Nakasujja N; Kisakye A; Batte J; Mayanja R; Anok A; Reynolds SJ; Quinn TC; Gray R; Wawer MJ; Sacktor N; Rubin LH
J Acquir Immune Defic Syndr; 2020 Aug; 84(5):534-542. PubMed ID: 32692113
[TBL] [Abstract][Full Text] [Related]
15. Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults.
Bharti AR; McCutchan A; Deutsch R; Smith DM; Ellis RJ; Cherner M; Woods SP; Heaton RK; Grant I; Letendre SL
Clin Infect Dis; 2016 Dec; 63(12):1655-1660. PubMed ID: 27794019
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Intracellular Cystatin B Levels Are Altered in HIV-Infected Participants With Respect to Neurocognitive Status and Antiretroviral Therapy.
Opsteen S; Moylan D; Taiwo BO; Robertson KR; Overton ET; Cutter GR; Sabbaj S; Heath SL; Shacka JJ
J Acquir Immune Defic Syndr; 2022 Dec; 91(5):485-489. PubMed ID: 36083516
[TBL] [Abstract][Full Text] [Related]
17. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
Reid A; Stöhr W; Walker AS; Williams IG; Kityo C; Hughes P; Kambugu A; Gilks CF; Mugyenyi P; Munderi P; Hakim J; Gibb DM;
Clin Infect Dis; 2008 Apr; 46(8):1271-81. PubMed ID: 18444867
[TBL] [Abstract][Full Text] [Related]
18. Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
Mastrorosa I; Pinnetti C; Brita AC; Mondi A; Lorenzini P; Del Duca G; Vergori A; Mazzotta V; Gagliardini R; Camici M; De Zottis F; Fusto M; Plazzi MM; Grilli E; Bellagamba R; Cicalini S; Antinori A
Clin Infect Dis; 2023 Feb; 76(3):e629-e637. PubMed ID: 35982541
[TBL] [Abstract][Full Text] [Related]
19. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK;
Clin Infect Dis; 2017 Apr; 64(8):1006-1016. PubMed ID: 28329393
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Mugavero MJ; May M; Ribaudo HJ; Gulick RM; Riddler SA; Haubrich R; Napravnik S; Abgrall S; Phillips A; Harris R; Gill MJ; de Wolf F; Hogg R; Günthard HF; Chêne G; D'Arminio Monforte A; Guest JL; Smith C; Murillas J; Berenguer J; Wyen C; Domingo P; Kitahata MM; Sterne JA; Saag MS; ; ; ;
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):253-60. PubMed ID: 21857357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
